Abstract:FK506 is an efficient immunosuppressive agent with an increasing number of clinical applications. It has been approved to prevent rejection in transplant patients and be efficacious in several autoimmune diseases. Its immunosuppressive activity results from binding to receptor proteins designated as immunophilins (i.e., FKBP 12, FK506 binding protein). Recent studies have suggested that FK506 can promote neurite Outgrowth as a 2nd activity. Furthermore, it has been shown that the neurotrophic property of FK506 is independent of its immunosuppressive action. Although the mechanism of its neurotrophic activity has not yet been well elucidated, FKBP12 is identified as a drug target, and much effort has been directed toward the design of FKBP12-binding molecules, which are neurotrophic but nonimmunosuppressive, for clinical use. In this present study, the authors constructed a stable cell line, which underwent apoptosis upon treatment by AP20187, a wholly synthesized, cell-permeable dimeric FK506 derivative, based on FKBP12-mBax dimerization. This AP20187-mediated apoptosis was rapidly reversed by the addition of an FKBP12-binding competitor molecule (FK506 or rapamycin), indicating that this cell line might be used to screen FK506 derivatives. Using the screening model, hundreds of synthetic FK506 analogs were analyzed. A promising compound, named N308, was obtained. The results showed that N308 could inhibit AP20187-induced gene-modified target cell apoptosis and elicit augmentation of neurite extension from both cultured PC-12 cells and chicken dorsal root ganglia cultures.

Crystallization and Preliminary X-ray Diffraction Analysis of FKBP12 Complexed with a New Neurotrophic Ligand*

Crystallization and preliminary X-ray diffraction analysis of FKBP52 N-terminal domain.

Crystallization and preliminary crystallographic studies of the C-terminal domain of human FKBP52.

Design and structure-based study of new potential FKBP12 inhibitors.

Structural Characterization of the RyR1-FKBP12 Interaction.

Crystallization and Preliminary X-ray Crystallographic Analysis of the Human CKIP-1 Pleckstrin Homology Domain.

Crystallization and Preliminary Crystallographic Analysis of the Extracellular Fragment of FcalphaRI/CD89.

Crystallization and preliminary crystallographic studies of human coactosin-like protein (CLP).

Crystallization and preliminary crystallographic analysis of the extracellular fragment of Fc[alpha]RI/CD89

The Crystal Structure of (E)-3-chloro-2-(2-(2-fluorobenzylidene)hydrazinyl)pyridine, C12H9ClFN3

Crystallization and preliminary crystallographic analysis of allograft inflammatory factor 1.

Crystallization and Preliminary X-ray Crystallographic Studies of Human FAIM Protein.

Protein Preparation, Crystallization and Preliminary X-Ray Analysis of the C-Terminal Domain of Human Rsk1 Serine/Threonine Protein Kinase

Crystallization and Preliminary Crystallographic Analysis of Recombinant Human Calcyphosine.

Crystallization and Preliminary Crystallographic Analysis of Human Ca 2+-Loaded Calbindin-D28k.

Expression and bioactivity of human FKBP12 gene

Crystallization and preliminary X-ray diffraction studies of the calcium-binding protein CalD from Streptomyces coelicolor.

Crystallization and Preliminary X-ray Crystallographic Analysis of Yeast Prion Protein Ure2p with Shortened N-terminal

Expression, Crystallization and Preliminary X-ray Analysis of a Ferric Binding Protein Fromthermus Thermophilushb8

Establishment of A Cell Model Based on Fkbp12 Dimerization for Screening of Fk506-Like Neurotrophic Small Molecular Compounds

Crystallization and Preliminary X-ray Crystallographic Analysis of Osteoclast-Stimulating Factor